A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2016 Planned End Date changed from 1 Dec 2019 to 1 Oct 2020.